SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing a massive sell-off as a weak revenue outlook and significant declines in the China market overshadow an earnings beat, fueling intense debate over whether this decade-long low represents a generational buying opportunity or a deeper structural decline. The community is sharply divided, with many traders betting on a sharp V-shaped recovery and a "juicy" dividend, while skeptics argue that the brand's long-term growth is dead and are cautioning against catching a falling knife.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as market participants weigh conflicting reports regarding geopolitical tensions in the Middle East and anticipated commentary from political leadership. Investors are actively debating whether recent gains represent a durable recovery or a bull trap, with many closely monitoring crude oil fluctuations and potential impacts on global trade as they hedge against significant uncertainty ahead of scheduled policy speeches.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as the community closely monitors the company's progress on scaling its proprietary hydrometallurgical facility in Bolivia and its upcoming implementation in Idaho. Investors are actively discussing the potential impact of this technology on processing critical minerals, alongside speculation regarding anticipated Department of Defense shipments and the broader strategic necessity of domestic supply chains for antimony and tungsten.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense community debate over its aggressive Bitcoin-linked treasury strategy, with investors highlighting significant price volatility and concerns regarding share dilution. The conversation is currently split between those betting on long-term institutional adoption and short sellers pointing to structural leverage risks and downward price action.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing intense volatility and social media attention as traders monitor its low-float structure and history of sharp, squeeze-driven price moves. The community is actively debating whether current price action signals a repeat of past parabolic runs, with many focusing on the high cost to borrow, limited share availability, and the potential for a swift short squeeze.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust is experiencing intense volatility and aggressive price action as traders weigh conflicting reports regarding potential ceasefire negotiations in the Iran conflict. The community is actively debating whether the current rally is a sustainable recovery or an exit liquidity trap fueled by market manipulation ahead of a highly anticipated national address by the President.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is facing significant selling pressure as investors grapple with shifting consumer sentiment and broader market volatility, with community discussions split between long-term growth optimism and concerns regarding current valuation levels. The stock is currently under a microscope as market participants debate whether these lows present a buying opportunity or a warning sign of further downward consolidation.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is trending due to significant volatility following a quarterly earnings report that featured a revenue beat but a notable miss on earnings expectations, coupled with cautious guidance linked to ongoing tariff pressures and housing market headwinds. Investors are actively debating the stock's future, weighing concerns over debt and luxury spending against potential upside from long-term global expansion and anticipation of favorable legal outcomes regarding trade tariffs.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is currently facing intense selling pressure driven by a mix of weak quarterly earnings, concerns regarding equity dilution, and a class-action lawsuit alleging misleading disclosures about project partnerships. Despite this negative sentiment and short-term volatility, the community remains divided, with long-term investors pointing to the growing demand for nuclear energy in AI data centers as a reason to accumulate shares while traders monitor critical support levels.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following an update from its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer, which triggered a significant stock pullback amid investor scrutiny over safety profiles at higher doses. The community is actively debating whether the selloff is an overreaction to trial data, with many bulls highlighting the company's strong cash position and clinical potential versus skeptics pointing to broader sector safety concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Incannex stated that its financial position is strong, with about $75 million in cash and no debt on its books.</li><li>The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.</li><li>Incannex is currently undertaking trials of IHX-42X and PSX-001 for the treatment of Obstructive Sleep Apnea and Generalized Anxiety Disorder, respectively.</li></ul>Incannex Healthcare Inc. (IXHL) on Friday announced that it has reactivated its share repurchase program, saying that it has been active over the past two trading days.The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.Incannex stated that it intends to continue utilizing the share repurchase program “opportunistically.”<a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare</a> shares gained more than 6% in Friday’s opening trade before paring some of the gains. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Incannex Touts Financial Strength</h2>The company stated that its financial position is strong, with about $75 million in cash and no debt on its books.“We are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner,” said Incannex CEO Joel Latham.Incannex is currently undertaking trials of IHX-42X and PSX-001, its treatments for Obstructive Sleep Apnea (OSA) and Generalized Anxiety Disorder (GAD), respectively.The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.<h2 class="st-heading-2">Incannex’s Obstructive Sleep Apnea Trial</h2>Incannex stated that Phase 2 clinical trials showed that IHX-42X’s lowest dose is the most effective for addressing OSA, reducing the Apnea-Hypopnea Index (AHI) by 51% compared with baseline. Incannex stated that one in four participants reported an 80% reduction in AHI.AHI is a key metric for gauging the severity of OSA, measuring how many apneas (complete breathing pauses) and hypopneas (partial airway blockages) occur per hour of sleep.The company said a global Phase 2/3 trial is currently underway to assess the efficacy and safety of IHL-42X.<h2 class="st-heading-2">Incannex’s Generalized Anxiety Disorder Trial</h2>The company noted that in the Phase 2 clinical trial of PSX-001 for the treatment of Generalized Anxiety Disorder (GAD), 44% of the participants who received the treatment reported a clinically meaningful or at least a 50% reduction in their anxiety scores.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> is down 68% year-to-date and 84% over the past 12 months. AdvisorShares Psychedelics ETF (PSIL) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gctk-stock-soaring-today/cZ3HcZMRIlU">GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Incannex Healthcare - The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

IXHL Stock Gains As Incannex Reactivates Share Repurchase Program

Equity

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

Incannex Healthcare Stock Falls 35% Over Announcement Of IHL-42X Development Plan, Stock Offering

(RTTNews) - Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its...

<ul class="summary-bullets"><li>If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million.</li><li>The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program.</li><li>Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements, reducing breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.</li></ul>Shares of Incannex Healthcare Inc (IXHL) fell 35% on Thursday, after the company announced the pricing of its $10 million private placement. The company also shared that the Phase 3 development of its oral drug candidate for obstructive sleep apnea is not expected to begin until the second half of 2027.The company plans to issue 2 million shares of common stock, or equivalents, along with warrants to purchase up to another 2 million shares at a combined price of $5.00 per share and accompanying warrant. IHXL shares closed at $5.97 in the previous session.&nbsp;Incannex announced that it has ceased using its at-the-market (ATM) facility and has no plans to use it again.If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million, bringing total potential proceeds to about $23 million. The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program, while existing cash will remain available for planned Phase 3 development expected to begin in the second half of 2027.<h2 class="st-heading-2">Incannex’s Plan Ahead</h2>The firm said it has updated the clinical development strategy for its oral drug candidate IHL-42X, to treat obstructive sleep apnea, after positive results from its Phase 2 study. The therapy has also received Fast Track designation from the U.S. Food and Drug Administration.The company intends to run a Phase 2 crossover study, known as DReAMzz, to optimize the drug’s dosage before advancing to a streamlined Phase 3 program. The study aims to improve dosing precision and build stronger clinical data ahead of late-stage development.Results from the Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements. The treatment reduced breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp selloff, retail sentiment for <a href="https://stocktwits.com/symbol/IXHL">IXHL</a> on Stocktwits turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said that while the financing itself isn’t too negative, management’s communication regarding the delayed Phase 3 trial has been poor.<stembedurl>https://stocktwits.com/pavaaan/message/647327564</stembedurl>Another user said the offering “looks worse than it actually is.”<stembedurl>https://stocktwits.com/SurfyKnagg/message/647333529</stembedurl>Year-to-date, the stock has slumped 66%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Slump 35% Today?

The company priced its private placement at $5 per share, below its previous closing price of $5.97, and said the proceeds would be used for its Phase 3 treatment for sleep apnea, which is expected to begin in the second half of 2027.

<ul class="summary-bullets"><li>To support compliance, Incannex implemented a 1-for-30 reverse stock split on Feb. 26, reducing the number of outstanding shares from 358 million to about 11.9 million.</li><li>Interest has also been driven by regulatory progress for the company’s sleep apnea drug, which received Fast Track designation from the FDA in December.</li><li>Incannex plans to advance the sleep apnea therapy toward late-stage development this year.</li></ul>Shares of Incannex Healthcare (IXHL) surged to their strongest session in five months on Wednesday as investors looked ahead to potential Nasdaq compliance and upcoming regulatory discussions for the company’s sleep apnea drug.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped over 19% on Wednesday to close at $5.97, marking the company’s third straight session of gains.<h2 class="st-heading-2">Nasdaq Compliance Timeline</h2>Incannex said in October that Nasdaq had granted it a 180-day extension to regain compliance with the exchange’s minimum bid price requirement, giving the company until April 20 to meet the rule. Under Nasdaq guidelines, companies must maintain a closing bid price of at least $1 for at least 10 consecutive trading days to regain compliance.As part of its efforts to regain compliance, Incannex implemented a 1-for-30&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ixhl-stock-tank-over-today/cZRy4khRIGO">reverse stock split</a> effective Feb. 26, with trading on a split-adjusted basis beginning the following day. The move reduced the company’s outstanding share count from 358 million to 11.9 million shares, while lifting its per-share price.<h2 class="st-heading-2">Regulatory Catalyst For Sleep Apnea Drug</h2>Investor interest has also been supported by regulatory momentum for the company’s lead obstructive sleep apnea therapy, IHL-42X, which received&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/incannex-healthcare-stock-soars-15-after-fda-fast-tracks-obstructive-sleep-apnea-drug/cLIXxacRE1t">Fast Track designation</a> from the U.S. Food and Drug Administration in December.The designation followed positive results from the company’s Phase 2 RePOSA study, which showed the therapy significantly reduced breathing interruptions during sleep, with reductions of up to 83% in some patients, along with positive patient feedback and a favorable safety profile.Fast Track status allows for more frequent meetings with the FDA, eligibility for rolling review of a future drug application, and the possibility of accelerated approval or priority review if the therapy meets relevant criteria. Incannex expects to receive written feedback from the FDA on its Phase 2 data package and clinical development strategy, which will help determine the path toward late-stage clinical development.<h2 class="st-heading-2">Clinical Pipeline Backed By Solid Cash Runway</h2>Incannex has also highlighted a strengthened financial position as it advances its clinical pipeline. In January, the company said it entered 2026 with more than $70 million in cash, providing an operating runway well into 2027.During 2025, the company reported two positive Phase 2 clinical readouts, including results for its sleep apnea program and a separate psilocybin-based therapy for generalized anxiety disorder. Incannex said it plans to advance the sleep apnea program toward later-stage development, while continuing regulatory planning for the anxiety treatment this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IXHL was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ixhl_ss_png_a8ed2aecde.webp" alt="ixhl ss.png" width="973" height="141"><figcaption>IXHL sentiment and message volume as of March 12 | Source: Stocktwits</figcaption></figure>One user <a href="https://stocktwits.com/Santa_Claus_Trades/message/647252179">said</a> they were continuing to hold their position and planned to add shares ahead of the Nasdaq compliance window, noting the stock often moves higher heading into potential news, including a possible announcement of an end-of-Phase 2 meeting.<stembedurl>https://stocktwits.com/Santa_Claus_Trades/message/647252179</stembedurl>Another user <a href="https://stocktwits.com/Nawaf643/message/647272427">said</a>, “Tomorrow is Day 10 above $1 — compliance locked. The real show may start after that. Be ready… big news could start dropping as soon as tomorrow.”<stembedurl>https://stocktwits.com/Nawaf643/message/647272427</stembedurl>IXHL stock has declined 73% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

IXHL Stock - Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 842,808 shares, a drop of...

Incannex Healthcare (NASDAQ:IXHL) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Incannex Healthcare to a "sell" rating in a report on Saturday...

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - Here's Why...

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 21,688,567...

Incannex Healthcare (NASDAQ:IXHL) Announces Quarterly Earnings Results

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) issued its earnings results on Friday. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR